FDA weighs muddled data on experimental drug for devastating disease; what's behind the recent surge in Apellis' stock price

Taking stock of the drug industry, from the lab to the medicine chest

August 14, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mike Reddy for STAT STAT+ | In the case of a devastating disease, the FDA weighs an experimental drug's muddled data and a desperate need Patients with FOP, a rare genetic disorder that causes their body to grow rigid bone where it doesn't belong, are desperate for treatment. By Andrew Joseph and Damian Garde STAT+ | What's behind the recent surge in Apellis' stock price? Growing confidence in the safety of its eye treatment Concern over a rare side effect — one that could cause blindness — initially sent Apellis' stock price plunging. By Adam Feuerstein STAT+ | Hospitals are dialing back on venture capital investing Many hospitals are now dialing back on venture capital investing in an era of tight margins. Some say they never quite got it right. By Tara Bannow Courtesy United STAT+ | After Optum Health's lowest profit margin in a decade, UnitedHealth makes changes Just weeks after a division of UnitedHealth posted its lowest profit margin in a decade, the company shuffled around several executives. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •     Contact Us     •     Advertise with Us     •     View in Browser